Kinetics of cis-dichlorodiammineplatinum. 1979

P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk

The cancer chemotherapeutic cis-dichlorodiammineplatinum (cis-DDP) was administered to 8 patients (1-hr intravenous infusion) at a dose of 70 mg/m2. Plasma and urine concentrations of platinum were determined by flameless atomic absorption spectrometry. Measured plasma platinum concentrations revealed a biphasic clearance of platinum with half-life values of 23 min and 67 hr. Platinum values obtained 3 wk after the infusion indicated that a third excretory phase might be present. Urinary measurements showed 17 +/- 2.7% of the administered dose excreted in the first 4 hr and 23 +/- 3.9% excreted in the first 24 hr. Renal excretion appears to be predominantly by glomerular filtration. Non-protein-bound plasma platinum values were calculated and the non-protein-bound platinum was found to be rapidly and biphasically cleared from the plasma with half-life values of 8 to 10 min and 40 to 45 min.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007939 Leukemia L1210 An experimental LYMPHOCYTIC LEUKEMIA of mice. Leukemia L 1210,L 1210, Leukemia,L1210, Leukemia
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D010984 Platinum A heavy, soft, whitish metal, resembling tin, with atomic number 78, atomic weight 195.084, symbol Pt. It is used in manufacturing equipment for laboratory and industrial use. It occurs as a black powder (platinum black) and as a spongy substance (spongy platinum) and may have been known in Pliny's time as "alutiae". Platinum Black
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D001798 Blood Proteins Proteins that are present in blood serum, including SERUM ALBUMIN; BLOOD COAGULATION FACTORS; and many other types of proteins. Blood Protein,Plasma Protein,Plasma Proteins,Serum Protein,Serum Proteins,Protein, Blood,Protein, Plasma,Protein, Serum,Proteins, Blood,Proteins, Plasma,Proteins, Serum
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002470 Cell Survival The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability. Cell Viability,Cell Viabilities,Survival, Cell,Viabilities, Cell,Viability, Cell
D002945 Cisplatin An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle. Platinum Diamminodichloride,cis-Diamminedichloroplatinum(II),cis-Dichlorodiammineplatinum(II),Biocisplatinum,Dichlorodiammineplatinum,NSC-119875,Platidiam,Platino,Platinol,cis-Diamminedichloroplatinum,cis-Platinum,Diamminodichloride, Platinum,cis Diamminedichloroplatinum,cis Platinum
D005260 Female Females

Related Publications

P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk
January 1987, European journal of drug metabolism and pharmacokinetics,
P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk
January 1979, Cancer treatment reports,
P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk
April 1982, Gan to kagaku ryoho. Cancer & chemotherapy,
P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk
January 1979, Cancer treatment reports,
P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk
January 1979, Cancer treatment reports,
P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk
January 1979, Cancer treatment reports,
P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk
January 1979, Cancer treatment reports,
P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk
July 1980, Cell biology international reports,
P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk
July 1978, Cancer treatment reports,
P E Gormley, and J M Bull, and A F LeRoy, and R Cysyk
December 1971, Biochimica et biophysica acta,
Copied contents to your clipboard!